Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer

Dong,Lei; Zhu,Jianjun; Wen,Xiaoxia; Jiang,Tingting; Chen,Yao

doi:10.3892/ol.2014.1866

Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer

Authors:
- Lei Dong
- Jianjun Zhu
- Xiaoxia Wen
- Tingting Jiang
- Yao Chen
View Affiliations

Affiliations: Department of Anatomy, Basic Medical and Forensic Medical Institute, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: February 11, 2014 https://doi.org/10.3892/ol.2014.1866
Pages: 1203-1208

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The SET oncoprotein is involved in cancer progression by modulating multiple cellular processes, including the inhibition of the tumor suppressor, protein phosphatase 2 (PP2A). Based upon these multiple activities, we hypothesized that targeted inhibition of SET is likely to have multiple discrete and measurable effects on cancer cells. In the present study, the mRNA expression levels of SET, PP2A and β‑catenin were examined in 31 pairs of human colorectal adenocarcinoma tissues and corresponding adjacent normal colorectal tissues by quantitative real‑time polymerase chain reaction (qPCR). A small interfering RNA targeting SET was transfected into the human colon carcinoma cell lines, LS174T and SW480. The mRNA levels of SET, PP2A, β‑catenin, c‑Myc, E‑cadherin and p53 were determined by qPCR analysis and the protein levels of SET, c‑Myc, PP2A and β‑catenin were examined by western blot analysis. mRNA expression levels of SET and β‑catenin were found to be elevated in 22 (70.9%) samples, while PP2A expression levels were upregulated in eight (25.8%) samples. In addition, the knockdown of SET mRNA expression caused the upregulation of PP2A and c‑Myc in the two cell lines, whereas β‑catenin, E‑cadherin and p53 mRNA expression was downregulated. Consistent with these results, the protein expression of β‑catenin and c‑Myc was found to be downregulated, whereas PP2A was upregulated at the protein level. Based on these results, we proposed that SET is essential in the carcinogenesis of human colorectal adenocarcinoma. In addition, it is suggested that SET promotes carcinogenesis through regulation of the Wnt signaling pathway.

View Figures

View References

1	Bosetti C, Levi F, Rosato V, Bertuccio P, Lucchini F, Negri E and La Vecchia C: Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 129:180–191. 2011. View Article : Google Scholar : PubMed/NCBI
2	Shu Z and Shanrong C: Colorectal cancer epidemiology and prevention study in China. Chin Ger J Clin Oncol. 2:72–75. 2003. View Article : Google Scholar
3	Chen Y, Zhang YZ, Zhou ZG, et al: Identification of differentially expressed genes in human colorectal adenocarcinoma. World J Gastroenterol. 12:1025–1032. 2006.
4	von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A and Grosveld G: Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol. 12:3346–3355. 1992.PubMed/NCBI
5	Li M, Makkinje A and Damuni Z: The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 271:11059–11062. 1996. View Article : Google Scholar : PubMed/NCBI
6	Jiang Q, Zhang C, Zhu J, Chen Q and Chen Y: The SET gene is a potential oncogene in human colorectal adenocarcinoma and oral squamous cell carcinoma. Mol Med Rep. 4:993–999. 2011.PubMed/NCBI
7	Van Vlierberghe P, van Grotel M, Tchinda J, et al: The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 111:4668–4680. 2008.PubMed/NCBI
8	Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, Macleod RA and Drexler HG: SET-NUP214 fusion in acute myeloid leukemia and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol. 2:32009. View Article : Google Scholar : PubMed/NCBI
9	Ouellet V, Le Page C, Guyot MC, LuSSier C, Tonin PN, Proveneher DM and Mes-Masson AM: SET complex in serous epithelial ovarian cancer. Int J Cancer. 119:2119–2126. 2006. View Article : Google Scholar : PubMed/NCBI
10	Bustin SA, Benes V, Garson JA, et al: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar : PubMed/NCBI
11	Nolan T, Hands RE and Bustin SA: Quantification of mRNA using real-time RT-PCR. Nat Protoc. 1:1560–1581. 2006. View Article : Google Scholar
12	Kim DW, Kim KB, Kim JY, Lee KS and Seo SB: Negative regulation of neuronal cell differentiation by INHAT subunit SET/TAF-Iβ. Biochem Biophys Res Commun. 400:419–425. 2010.PubMed/NCBI
13	Cristóbal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ and Odero MD: Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 97:543–550. 2012.
14	Neviani P, Santhanam R, Trotta R, et al: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 8:355–368. 2005. View Article : Google Scholar : PubMed/NCBI
15	Janssens V and Goris J: Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 353:417–439. 2001. View Article : Google Scholar : PubMed/NCBI
16	Arroyo JD and Hahn WC: Involvement of PP2A in viral and cellular transformation. Oncogene. 24:7746–7755. 2005. View Article : Google Scholar : PubMed/NCBI
17	Janssens V, Goris J and Van Hoof C: PP2A: the expected tumor suppressor. Curr Opin Genet. 15:34–41. 2005. View Article : Google Scholar : PubMed/NCBI
18	Arnold HK and Sears RC: Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol. 26:2832–2844. 2006. View Article : Google Scholar : PubMed/NCBI
19	Polakis P: Wnt signaling and cancer. Genes. 14:1837–1851. 2000.
20	He TC, Sparks AB, Rago C, et al: Identification of c-myc as a target of the APC pathway. Science. 281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
21	de La Coste A, Romagnolo B, Billuart P, et al: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 95:8847–8851. 1998.PubMed/NCBI
22	Yeh E, Cunningham M, Arnold H, et al: A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 6:308–318. 2004. View Article : Google Scholar
23	Willert K, Shibamoto S and Nusse R: Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes. 13:1768–1773. 1999. View Article : Google Scholar : PubMed/NCBI
24	Behrens J, Jerchow BA, Würtele M, et al: Functional interaction of an axin homologconductin, with β-catenin, APC and GSK3β. Science. 280:596–599. 1998.
25	Huang H and He X: Wnt/β-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 20:119–125. 2008.
26	Bienz M and Clevers H: Linking colorectal cancer to Wnt signaling. Cell. 103:311–320. 2000. View Article : Google Scholar : PubMed/NCBI
27	Tian X, Liu Z, Niu B, et al: E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011:5673052011.
28	Koldobskiy MA, Chakraborty A, Werner JK Jr, et al: p53-mediated apoptosis requires inositol hexakisphosphate kinase-2. Proc Natl Acad Sci USA. 107:20947–20951. 2010. View Article : Google Scholar